OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Leslie on Real-World Outcomes of Patients With CLL Treated With Acalabrutinib

January 8th 2020

Lori A. Leslie, MD, discusses a retrospective analysis of real-world patients with chronic lymphocytic leukemia who were treated with acalabrutinib (Calquence).

Dr. McCloskey on the Results of the ASCERTAIN Trial in MDS

January 8th 2020

James K. McCloskey II, MD, discusses the results of the phase III ASCERTAIN trial in myelodysplastic syndrome.

Dr. Goy on the Results of the FLYER Trial in DLBCL

January 8th 2020

Andre Goy, MD, MS, chief, discusses the results of the multicenter FLYER trial in patients with diffuse large B-cell lymphoma.

Dr. Rugo on Findings of Oral Paclitaxel With Encequidar in Metastatic Breast Cancer

January 8th 2020

Hope S. Rugo, MD, discusses results of a randomized phase III trial evaluating oral paclitaxel with encequidar in patients with metastatic breast cancer.

Dr. O'Malley on Remaining Questions in Ovarian Cancer

January 8th 2020

David O’Malley, MD, discusses remaining questions in the ovarian cancer field.

Dr. McDermott on the Use of PD-1 Inhibitor Combos in mRCC

January 8th 2020

David F. McDermott, MD, discusses the use of PD-1 inhibitors in combination with VEGF inhibitors and CTLA-4 inhibitors in metastatic renal cell carcinoma.

Dr. Rampal on Treatment Options in Polycythemia Vera

January 8th 2020

Raajit K. Rampal, MD, PhD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses treatment options in polycythemia vera.

Dr. Hwang on Choosing Agents for Prostate Cancer Treatment

January 8th 2020

Clara Hwang, MD, discusses factors that can be used to decide what agent to use in the frontline setting for patients with metastatic castration-sensitive or castration-resistant prostate cancer.

Dr. Chaudhry on DRd Triplet in Transplant-Ineligible Multiple Myeloma

January 7th 2020

Maria Chaudhry, MBBS, discusses the use of daratumumab (Darzalex), lenalidomide (Revlimid), and dexamethasone in transplant-ineligible patients with multiple myeloma.

Dr. Cusnir on the Utility of Regorafenib in Gastric Cancer

January 7th 2020

Mike Cusnir, MD, discusses the utility of regorafenib (Stivarga) in gastric cancer.

Dr. Luke on Current and Emerging Treatment Approaches in Metastatic Melanoma

January 7th 2020

Jason J. Luke, MD, FACP, discusses current and emerging treatment paradigms in metastatic melanoma.

Dr. Vulfovich on Molecular Testing in Colorectal Cancer

January 7th 2020

Michel Vulfovich, MD, discusses molecular testing in colorectal cancer.

The Development of Genetic Testing in Ovarian Cancer

January 7th 2020

Leigha Senter, MS, LGC, discusses the development of genetic testing in ovarian cancer.

Dr. Woyach on the Results of the ELEVATE-TN Trial in CLL

January 7th 2020

Jennifer Woyach, MD, discusses the results of the ELEVATE-TN trial in patients with treatment-naïve chronic lymphocytic leukemia.

Dr. Damon on Optimal Treatment Regimens in AYA ALL

January 6th 2020

Lloyd Damon, MD, discusses optimal treatment regimens in adolescent/young adult acute lymphoblastic leukemia.

Dr. Wang on the Benefit of BTK Inhibitors in MCL

January 6th 2020

Michael Wang, MD, discusses the benefit of BTK inhibitors in mantle cell lymphoma.

Dr. Alva on the Toxicity Profiles of TKIs in RCC

January 6th 2020

Ajjai Shivaram Alva, MBBS, discusses class-specific toxicities of TKIs in renal cell carcinoma.

Similarity of Biosimilars and Biologics

January 4th 2020

Thomas Helleday, PhD, professor of Translational Oncology, director of the Weston Park Cancer Centre, Department of Oncology and Metabolism, The Medical School, The University of Sheffield, discusses the similarity of biosimilars and biologics.

Dr. Lockhart on Next Steps for Regorafenib and TAS-102 in mCRC

January 4th 2020

A. Craig Lockhart, MD, MHS, professor, associate director for Regional and Strategic Clinical Research Affiliations, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses next steps for regorafenib (Stivarga) and TAS-102 (trifluridine/tipiracil; Lonsurf) in metastatic colorectal cancer (mCRC).

Dr. Vidal on the Use of CDK4/6 Inhibitors in HER2+ Breast Cancer

January 4th 2020

Gregory Vidal, MD, PhD, assistant professor, Department of Hematology/Oncology, The University of Tennessee Health Science Center, and medical oncologist, West Cancer Center, discusses the potential use of CDK4/6 inhibitors in HER2-positive breast cancer.